Clinical Trial Detail

NCT ID NCT03068455
Title A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

melanoma

Therapies

Nivolumab

Ipilimumab

Ipilimumab + Nivolumab

Age Groups: child senior adult

No variant requirements are available.